uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-beta Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
Show others and affiliations
2015 (English)In: Journal of Alzheimer's Disease, ISSN 1387-2877, Vol. 43, no 2, 575-588 p.Article in journal (Refereed) Published
Abstract [en]

Amyloid-beta (A beta) immunotherapy for Alzheimer's disease (AD) has good preclinical support from transgenic mouse models and clinical data suggesting that a long-term treatment effect is possible. Soluble A beta protofibrils have been shown to exhibit neurotoxicity in vitro and in vivo, and constitute an attractive target for immunotherapy. Here, we demonstrate that the humanized antibody BAN2401 and its murine version mAb158 exhibit a strong binding preference for A beta protofibrils over A beta monomers. Further, we confirm the presence of the target by showing that both antibodies efficiently immunoprecipitate soluble A beta aggregates in human AD brain extracts. mAb158 reached the brain and reduced the brain protofibril levels by 42% in an exposure-dependent manner both after long-term and short-term treatment in tg-ArcSwe mice. Notably, a 53% reduction of protofibrils/oligomers in cerebrospinal fluid (CSF) that correlated with reduced brain protofibril levels was observed after long-term treatment, suggesting that CSF protofibrils/oligomers could be used as a potential biomarker. No change in native monomeric A beta(42) could be observed in brain TBS extracts after mAb158-treatment in tg-ArcSwe mice. By confirming the specific ability of mAb158 to selectively bind and reduce soluble A beta protofibrils, with minimal binding to A beta monomers, we provide further support in favor of its position as an attractive new candidate for AD immunotherapy. BAN2401 has undergone full phase 1 development, and available data indicate a favorable safety profile in AD patients.

Place, publisher, year, edition, pages
2015. Vol. 43, no 2, 575-588 p.
Keyword [en]
Alzheimer's disease, amyloid-beta, antibody, BAN2401, biomarker, cerebrospinal fluid, immunotherapy, mAb158, oligomer, protofibrils
National Category
URN: urn:nbn:se:uu:diva-240058DOI: 10.3233/JAD-140741ISI: 000345455300021PubMedID: 25096615OAI: oai:DiVA.org:uu-240058DiVA: diva2:777072
Available from: 2015-01-08 Created: 2015-01-05 Last updated: 2015-01-08Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lannfelt, Lars
By organisation
In the same journal
Journal of Alzheimer's Disease

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 324 hits
ReferencesLink to record
Permanent link

Direct link